Skip to main content
Search form
Home
About Heron
Company Overview
IITs, Grants, Sponsorships, and Contributions
Management
Board of Directors
Compliance
Contact Us
Careers
Our Focus
Our Mission
Our Technologies
About the 505(
b
)(2) Regulatory Pathway
Product Portfolio
Pipeline
SUSTOL
®
CINVANTI
®
HTX-011
Patient/Investigator Resources
About Chemotherapy-Induced Nausea and Vomiting (CINV)
About Pain Management
Scientific Posters and Presentations
Publications
Investor Resources
Investor Resources Home
News, Events and Presentations
News Releases
Events and Webcasts
Corporate Presentations
SEC Filings
Stock Information
Stock Quote
Stock Chart
Analyst Coverage
Corporate Governance
Board of Directors
Committee Composition
Corporate Governance Documents
Information Request
Material Request
E-mail Alerts
RSS Feeds
Developing Best-in-Class Medicine. Improving Lives.
Recent News
February 19, 2020
|
Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain
February 18, 2020
|
Heron Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
January 13, 2020
|
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
More News
Quick Links
Pipeline
Corporate Presentation
Scientific Posters and Presentations
